Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Alisertib (Primary) ; Irinotecan; Temozolomide
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 24 Apr 2019 Status changed from active, no longer recruiting to completed.
- 11 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 11 Mar 2019 Planned primary completion date changed from 1 Feb 2018 to 26 May 2019.